Abstract |
There have been critical problems in the non-surgical treatment for bladder cancer, especially residence to intravesical pharmacotherapy, including BCG immunotherapy, cisplatin-based chemotherapy, and radiotherapy. Recent preclinical and clinical evidence has suggested a vital role of sex steroid hormone-mediated signaling in the progression of urothelial cancer. Moreover, activation of the androgen receptor and estrogen receptor pathways has been implicated in modulating sensitivity to conventional non-surgical therapy for bladder cancer. This may indicate the possibility of anti-androgenic and anti-estrogenic drugs, apart from their direct anti- tumor activity, to function as sensitizers of such conventional treatment. This article summarizes available data suggesting the involvement of sex hormone receptors, such as androgen receptor, estrogen receptor-α, and estrogen receptor-β, in the progression of urothelial cancer, focusing on their modulation for the efficacy of conventional therapy, and discusses their potential of overcoming therapeutic resistance.
|
Authors | Hiroki Ide, Hiroshi Miyamoto |
Journal | Cells
(Cells)
Vol. 10
Issue 5
(05 11 2021)
ISSN: 2073-4409 [Electronic] Switzerland |
PMID | 34064926
(Publication Type: Journal Article, Review)
|
Chemical References |
- AR protein, human
- Androgen Antagonists
- Antineoplastic Agents
- BCG Vaccine
- Estrogen Receptor beta
- Gonadal Steroid Hormones
- Receptors, Androgen
- Receptors, Estrogen
- Cisplatin
|
Topics |
- Androgen Antagonists
(therapeutic use)
- Animals
- Antineoplastic Agents
(pharmacology)
- BCG Vaccine
- Cisplatin
(therapeutic use)
- Estrogen Receptor beta
(metabolism)
- Gonadal Steroid Hormones
(metabolism)
- Humans
- Immunohistochemistry
- Immunotherapy
- Mice
- Radiotherapy
- Receptors, Androgen
(metabolism)
- Receptors, Estrogen
(metabolism)
- Signal Transduction
- Urinary Bladder Neoplasms
(metabolism, therapy)
|